Email Artikel ini REVIEW: PERKEMBANGAN RESISTENSI ANTIBIOTIK MEROPENEM TERHADAP BAKTERI PSEUDOMONAS AERUGINOSA, ACINETOBACTER BAUMANNNII, SERTA KLEBSIELLA PNEUMONIAE DI INDONESIA
Abstrak
Teks Lengkap:
PDFReferensi
Afifah, A., Purwonegoro, T., & Peramiarti, I. (2017). RESISTENSI Klebsiella sp. TERHADAP MEROPENEM DI RSUD PROF. DR. MARGONO SOEKARJO PURWOKERTO. Scripta Biologica, 4(2), 135.
Alillah, S., Nasrul, E., & Alia, E. (2020). Prevalensi dan Pola Sensitivitas Antibiotik Klebsiella pneumoniae dan Escherichia coli Penghasil Extended Spectrum Beta Laktamase di RSUP Dr. M Djamil Padang. Jurnal Kesehatan Andalas. 9. 189.
Alvarez-Lerma F, Grau S. (2012). Management of antimicrobial use in the intensive care unit. Drugs;72(4):447–70. 18.
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016). Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial drug resistance (Larchmont, N.Y.), 22(5), 412–431.
Anggraini, D., Nasmah, A., & Andrini, F. (2019). Pola Sensitivitas Isolat Klinis Bakteri Gram Negatif Multiresisten Obat Terhadap Fosfomisin dari Beberapa Rumah Sakit Kota Pekanbaru. Jurnal Ilmu Kedokteran, 13(1), 28.
Anggraini, D., Yulindra, U., & Savira, M. (2018). Prevalensi dan Pola Sensitivitas Antimikroba Multidrug Resistant Pseudomonas aeruginosa di RSUD Arifin Achmad. Majalah Kedokteran Bandung, 50(1), 6-12.
Blair, J. M., Webber, M. A., Baylay, A. J., Ogbolu, D. O., & Piddock, L. J. (2015). Molecular mechanisms of antibiotic resistance. Nature reviews. Microbiology, 13(1), 42–51.
Botelho J, Grosso F, Peixe L. (2019). Antibiotic resistance in Pseudomonas aeruginosa–mechanisms, epidemiology and evolution. Drug Resist Update, 44:100640.
Bush K, Bradford PA.(2016). beta-Lactams and beta-lactamase inhibitors: an overview. Cold Spring Harb Perspect Med;6:a025247.
Cai B, Echols R, Magee G, Arjona Ferreira JC, Morgan G, Ariyasu M, et al. (2017). Prevalence of Carbapenem-resistant gram-negative infections in the United States predominated by Acinetobacter baumannii and Pseudomonas aeruginosa. ofx176 Open Forum Infect Dis;4
Cai Y, Chai D, Wang R, Liang B, Bai N. (2012). Kolistin resistance of Acinetobacter baumannii: clinical report, machanism and antimicrobial strategies. J Antimicrob Chemother;67:1607-15.
Cai, Y., Lee, W., & Kwa, A. L. (2015). Polymyxin B versus colistin: an update. Expert review of anti-infective therapy, 13(12), 1481–1497.
Castanheira M, Deshpande LM, Costello A, Davies TA, Jones RN. (2014). Epidemiology and carbapenem resistance mechanisms of carbapenem-non-susceptible Pseudomonas aeruginosa collected during 2009–11 in 14 European and Mediterranean countries. J Antimicrob Chemother;69:1804–1814.
Castanheira M, Huband MD, Mendes RE, Flamm RK. (2017). Meropenem-vaborbactam tested against contemporary Gram-negative isolates collected worldwide during 2014, including carbapenem-resistant, KPC-producing, multidrug-resistant, and extensively drug-resistant Enterobacteriaceae. Antimicrob Agents Chemother;61:e00567–e617.
Cerceo, E., Deitelzweig, S. B., Sherman, B. M., & Amin, A. N. (2016). Multidrug-Resistant Gram-Negative Bacterial Infections in the Hospital Setting: Overview, Implications for Clinical Practice, and Emerging Treatment Options. Microbial drug resistance (Larchmont, N.Y.), 22(5), 412–431.
Delgado-Valverde M, Sojo-Dorado J, Pascual (2013). A.Clinical Management of Infection Caused by Multidrug-resistant Enterobactectericeae. Ther Adv Infec Dis. 1(2); 49-69.
Deni, J., & JV Pangalila. (2019). Hubungan keberhasilan terapi pneumonia nosokomial resisten Pseudomonas aeruginosa dan Acinetobacter baumannii dengan dosis Karbapenem di ICU RS Royal Taruma periode 2012-2017. Tarumanagara Medical Journal, 2(1).
Doi Y. (2019). Treatment Options for Carbapenem-resistant Gram-negative Bacterial Infections. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 69(Suppl 7), S565–S575.
Donlan, R. M., & Costerton, J. W. (2002). Biofilms: survival mechanisms of clinically relevant microorganisms. Clinical microbiology reviews, 15(2), 167–193.
Drugbank. 2005. Tersedia di https://go.drugbank.com/drugs/DB00760 [Diakses pada 5 Juli 2022]
Dumitru, I., Dumitrascu, M., Vlad, N., Cernat, R., Ilie-Serban, C., Hangan, A., Slujitoru, R., et al. (2021). Carbapenem-Resistant Klebsiella pneumoniae Associated with COVID-19. Antibiotics, 10(5), 561. MDPI AG
Elshamy AA, Aboshanab KM. (2020). A review on bacterial resistance to carbapenems: epidemiology, detection and treatment options. Future Sci OA 6 (3): 1-15
Estiningsih, D., Puspitasari, I., & Nuryastuti, T. (2016). Identifikasi infeksi multidrug-resistant organisms (MDRO) pada pasien yang dirawat di bangsal neonatal intensive care unit (NICU) rumah sakit. JURNAL MANAJEMEN DAN PELAYANAN FARMASI, 6(3), 243-248.
Fabian, P., Alimsardjono, L., & Indiastuti, D. (2020). Pola resistensi bakteri Pseudomonas aeruginosa dan Acinetobacter baumannii pada spesimen darah terhadap antibiotik golongan β-laktam dan aminoglikosida di Rumah Sakit DR. Soetomo periode Januari 2016 – Desember 2016. Jurnal Kedokteran Syiah Kuala, 20(1). doi: 10.24815/jks.v20i1.18296
Fishbain J, Peleg AY. (2010). Treatment of Acinetobacter infections. Clin Infect Dis 51(1): 79-84.
Galani I, Karaiskos I, Karantani I, Papoutsaki V, Maraki S, Papaioannou V et al. (2018). Epidemiology and resistance phenotypes of carbapenemase-producing Klebsiella pneumoniae in Greece, 2014 to 2016. Eurosurveillance 23:1700775
Gallagher J, MacDougall C. (2012). Antibiotics simplified, 2nd Edition. United States: David Cella
Gottesman, T., Fedorowsky, R., Yerushalmi, R., Lellouche, J., & Nutman, A. (2021). An outbreak of carbapenem-resistant Acinetobacter baumannii in a COVID-19 dedicated hospital. Infection prevention in practice, 3(1), 100113.
Gurung J, Khyriem AB, Banik A, Lyngdoh WV, Choudhury B, Bhattacharyya P. (2013). Association of biofilm production with multidrug resistance among clinical isolates of Acinetobacter baumannii and Pseudomonas aeruginosa from intensive care unit. Indian Journal of Critical Care Medicine. 17 : 214.
Han, J. H., Goldstein, E. J., Wise, J., Bilker, W. B., Tolomeo, P., & Lautenbach, E. (2017). Epidemiology of Carbapenem-Resistant Klebsiella pneumoniae in a Network of Long-Term Acute Care Hospitals. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 64(7), 839–844.
Herdiyanti, H., Alimsardjono, L., & Indiastuti, D. N. (2019). Resistance Patterns of Escherichia coli and Klebsiella pneumoniae Bacteria Against Amikacin, Ceftazidime, Meropenem, Nitrofurantoin Antibiotics in Elderly Patients with UTI in RSUD Dr. Soetomo. JUXTA: Jurnal Ilmiah Mahasiswa Kedokteran Universitas Airlangga, 10(1), 20–24.
Inggraini, M., Nurfajriah, S., Priyanto, J., & Ilsan, N. (2021). Antimicrobial susceptibility and molecular species identification of clinical carbapenem-resistant bacteria. Biodiversitas Journal Of Biological Diversity, 22(2).
Kementerian Kesehatan RI. (2015). Peraturan Menteri Kesehatan Republik Indonesia Nomor 8 Tahun 2015 Program Pengendalian Resistensi Antimikroba Di Rumah Sakit. Jakarta: Kementerian Kesehatan RI.
Khasanah, R. N., Puspitasari, I., Nuryastuti, T., & Yuniarti, N. (2020). Prevalensi Multidrug-Resistant Klebsiella pneumonia dan Evaluasi Kesesuaian Antibiotik Empiris Berdasarkan Nilai Prediksi Farmakokinetik Terhadap Outcome Klinis di RSUP Dr Soeradji Tirtonegoro Klaten. Majalah Farmaseutik, 16(1), 27-33.
Kuo SC, Chang SC, Wang HY, Lai JF, Chen PC, Shiau YR, Huang IW, Lauderdale TL, TSAR Hospitals. (2012). Emergence of extensively drug-resistant Acinetobacter baumannii complex over 10 years: nationwide data from the Taiwan Surveillance of Antimicrobial Resistance (TSAR) program. BMC Infect Dis 12:200.
Lameng, I. S. V., Budayanti, N. N. S., Prilandari, L. I., & Adhiputra, I. K. A. I. (2021). Antimicrobial Resistance Profile of MDR & Non-MDR Meropenem-Resistant Pseudomonas aeruginosa Isolates of Patients in Intensive Care Unit of Tertiary Hospital. Indonesian Journal of Tropical and Infectious Disease, 9(3), 152–159.
Longo F, Vuotto C, Donelli G. (2014). Biofilm formation in Acinetobacter baumannii. New Microbiol; 37(2): 119-27
Mayasari E, Siregar C. (2014). Prevalence of Acinetobacter baumannii isolated from clinical specimens in Adam Malik Hospital. Majalah Kedokteran Andalas; 37: 1.
Mayasari, E & Siregar, C. (2015). PREVALENCE OF ACINETOBACTER BAUMANNII ISOLATED FROM CLINICAL SPECIMENS IN ADAM MALIK HOSPITAL. Majalah Kedokteran Andalas. 37(1).
Nirwati, H., Hakim, M. S., Darma, S., Mustafa, M., & Nuryastuti, T. (2018). Detection of blaoxa genes and identification of biofilm-producing capacity of Acinetobacter baumannii in a tertiary teaching hospital, Klaten, Indonesia. The Medical journal of Malaysia, 73(5), 291–296.
Nordmann P, Poirel L. (2019). Epidemiology and diagnostics of Carbapenem resistance in Gram-negative Bacteria. Clin Infect Dis ;69(Suppl 7):S521–S528.
Nordmann, P., Cuzon, G., & Naas, T. (2009). The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. The Lancet. Infectious diseases, 9(4), 228–236.
Nordmann, P., Cuzon, G., & Naas, T. (2009). The real threat of Klebsiella pneumoniae carbapenemase-producing bacteria. The Lancet. Infectious diseases, 9(4), 228–236.
Oshima, K., Nakamura, S., Iwanaga, N., Takemoto, K., Miyazaki, T., Yanagihara, K., Miyazaki, Y., Mukae, H., Kohno, S., & Izumikawa, K. (2016). Efficacy of High-Dose Meropenem (Six Grams per Day) in Treatment of Experimental Murine Pneumonia Induced by Meropenem-Resistant Pseudomonas aeruginosa. Antimicrobial agents and chemotherapy, 61(1), e02056-16.
Oyong, N., Anggraini, D., & Karina (2016). Pola Resistensi Bakteri Penyebab Sepsis Neonatorum di Instalasi Perawatan Neonatus RSUD Arifin Achmad Riau. Sari Pediatri. 17. 435.
Podschun R, Ullmann U. (1988). Klebsiella spp. as nosocomial pathogens: epidemiology, taxonomy, typing methods, and pathogenicity factors. Clin Microbiol Rev;11:589–603.
Prasetyo, D., Herna, H., Mursinah, M., Ibrahim, F., & Bela, B. (2022). Uji In Vitro Beberapa Kombinasi Antibiotik Antipseudomonas terhadap Pseudomonas aeruginosa yang Resisten terhadap Karbapenem. Jurnal Kefarmasian Indonesia, 31-38.
Putra, Oki & Saputro, Iswinarno & Faizah, Ana. (2020). Case Report : Expanded-Spectrum Beta Lactamase-Producing Klebsiella pneumoniae in Burn Injury With Hospital Acquired Pneumonia. Pharmaceutical Journal of Indonesia. 005. (79-83).
Putri SI, Djamal A, Rahmatini. (2014). Sensitivitas bakteri penyebab sepsis neonatorum terhadap meropenem di neonatal intensive care unit dan perinatologi RSUP DR M Djamil Padang Padang Tahun 2012. Jurnal Kesehatan Andalas. 3(3):475 479
Qu, X,. et al. (2019). Surveillance of carbapenem-resistant Klebsiella pneumoniae in Chinese hospitals - A five-year retrospective study. Journal of Infection in Developing Countries. 31;13(12):1101- 1107.
Quinn, J. P., Alex E. Studemeister, Cathy A. DiVincenzo, & Stephen A. Lerner. (1988). Resistance to Imipenem in Pseudomonas aeruginosa: Clinical Experience and Biochemical Mechanisms. Reviews of Infectious Diseases, 10(4), 892–898.
Rahman, V., Anggraini, D., & Fauziah, D. (2015). POLA RESISTENSI Acinetobacter baumannii YANG DIISOLASI DI Intensive Care Unit (ICU) RSUD ARIFIN ACHMAD PROVINSI RIAU PERIODE 1 JANUARI HINGGA 31 DESEMBER 2014. Jurnal Online Mahasiswa Fakultas Kedokteran Universitas Riau, 2(2), 1-8.
Raisanen K, et al. (2019). Emergence of ceftazidime-avibactam-resistant Klebsiella pneumoniae during treatment, Finland, December 2018. Euro Surveill.24;
Siahaan, S., Herman, M. J., & Fitri, N. (2022). Antimicrobial Resistance Situation in Indonesia: A Challenge of Multisector and Global Coordination. Journal of tropical medicine, 2022, 2783300.
Soriano, A., Carmeli, Y., Omrani, A. S., Moore, L., Tawadrous, M., & Irani, P. (2021). Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review. Infectious diseases and therapy, 10(4), 1989–2034.
Spellberg B, Bonomo RA. (2014). The deadly impact of extreme drug resistance in Acinetobacter baumannii. Crit Care Med 42:1289–1291.
Tarini, N., Fatmawati, N., & Mayura, I. (2016). DETECTION METALLO-BETA-LACTAMASE GENE IMP-1 AND IMP-2 OF Pseudomonas aeruginosa CLINICAL ISOLATES IN SANGLAH HOSPITAL BALI. International Journal Of Biosciences And Biotechnology, 3(1).
Tortora G, Funke B, Case C. (2010). Microbiology: An introduction, 10th Edition. San Francisco: Pearson Benjamin Cummings
Tsioutis C, Kritsotakis EI, Karageorgos SA, Stratakou S, Psarologakis C, Kokkini S, Gikas A. (2016). Clinical epidemiology, treatment and prognostic factors of extensively drug-resistant Acinetobacter baumannii ventilator-associated pneumonia in critically ill patients. Int J Antimicrob Agents
van Duin D, Kaye KS, Neuner EA, Bonomo RA. (2013). Carbapenem-resistant Enterobacteriaceae: a review of treatment and outcomes. Diagn Microbiol Infect Dis. ;75:115–120
van Duin, D., & Bonomo, R. A. (2016). Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 63(2), 234–241.
Ventola C. L. (2015). The antibiotic resistance crisis: part 1: causes and threats. P & T : a peer-reviewed journal for formulary management, 40(4), 277–283.
Wahyunita., Sjahril R., Hamid F.(2021) Antibiotic Susceptibility Pattern in Clinical Isolates of Pseudomonas aeruginosa. Nusantara Medical Science Journal. 2021; 6(2): 66- 73.
WHO. 2017. WHO Priority Pathogens List for R&D of New Antibiotics. Tersedia di https://www.who.int/news/item/27-02-2017-who-publishes-list-of-bacteria-for-which-new-antibiotics-are-urgently-needed [Diakses 5 Jul 2022]
WHO. 2020. Global Antimicrobial Resistance and Use Surveillance System (GLASS) Report Early Implementation 2020. Available at https://apps.who.int/iris/rest/bitstreams/1277847/retrieve. [Acessed 9 Jul 2022]
Yan Z, et al. (2019). Prospective investigation of carbapenem-resistant Klebsiella pneumonia transmission among the staff, environment and patients in five major intensive care units, Beijing. J Hosp Infection ;101:150–157.
Yanyan Hu, Congcong Liu, Zhangqi Shen, Hongwei Zhou, Junmin Cao, Shi Chen, Huoyang Lv, Mingming Zhou, Qiang Wang, Long Sun, Qiaoling Sun, Fupin Hu, Yang Wang & Rong Zhang (2020) Prevalence, risk factors and molecular epidemiology of carbapenem-resistant Klebsiella pneumoniae in patients from Zhejiang, China, 2008–2018, Emerging Microbes & Infections, 9:1, 1771-1779,
Yunita, S., & Sukrama, D. (2015). Karakteristik Penderita Hospital Acquired Pneumonia Dan Ventilator Associated Pneumonia Yang Disebabkan Acinetobacter Baumannii Di Intensive Care Unitrsup Sanglah Dan Pola Kepekaannya Terhadap Antibiotik Selama November 2014 – JanuarI 2015. E-Jurnal Medika Udayana, .
Zhanel, G. G., Wiebe, R., Dilay, L., Thomson, K., Rubinstein, E., Hoban, D. J., Noreddin, A. M., & Karlowsky, J. A. (2007). Comparative review of the carbapenems. Drugs, 67(7), 1027–1052.
DOI: https://doi.org/10.24198/farmaka.v20i3.40708
DOI (PDF): https://doi.org/10.24198/farmaka.v20i3.40708.g19423
Refbacks
- Saat ini tidak ada refbacks.
Sitasi manajer:
Jurnal ini diindeks dalam:
Farmaka by Universitas Padjadjaran is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License
Copyright © 2013 Jurnal Farmaka - All Right Reserved